Covaxin, a potential vaccine being prepared by Bharat Biotech against the Coronavirus, is expected to be at least 60 per cent effective and the Hyderabad-based biotechnology company is readying to launch the same in Q2 of 2021, confirmed a top official of the company. The company is aiming for 60 per cent effectiveness of the vaccine but it could also be more, he added.
Bharat Biotech, in collaboration with ICMR, is working on Covaxin. Bharat Biotech commenced Phase III trials of the vaccine earlier this month, with 26,000 volunteers from 25 centres in India participating in it.
It is the largest clinical trial being conducted for a Coronavirus vaccine candidate in India. During the trial, the volunteers will be monitored over the next year to detect any occurrence of Covid-19 disease.
The volunteers will receive two intra-muscular injections approximately 28 days apart. The participants will be randomly assigned 1:1 to receive either two 6 microgram (mcg) injections of Covaxin or two shots of a placebo.
The trial is double-blinded which means that the investigators, the participants and the company will not be aware of who is assigned to which group. Earlier, Covaxin was evaluated in 1,000 subjects during phase 1 and 2 clinical trials.
This post was last modified on 23 November 2020 8:23 am
Victory Venkatesh and Trivikram Srinivas' AK47 is an iconic combination, but then it fizzled out…
Meenakshi Chaudhary was clicked celebrating Diwali at a party, and she picked a stunning traditional…
A busy highway in Egypt witnessed an unusual and shocking scene after a massive digital…
United States, president Donald Trump is one of the most unpredictable and volatile personalities in…
Andhra Pradesh Education Minister Nara Lokesh shared a positive health update on the Raptadu school…
Tech billionaire Elon Musk might have tasted profits in various streams of business in which…